NASDAQ:GYRE Gyre Therapeutics Q4 2024 Earnings Report $7.00 -0.33 (-4.50%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$7.02 +0.02 (+0.29%) As of 10/1/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gyre Therapeutics EPS ResultsActual EPS$0.01Consensus EPS $0.04Beat/MissMissed by -$0.03One Year Ago EPSN/AGyre Therapeutics Revenue ResultsActual Revenue$27.87 millionExpected Revenue$23.50 millionBeat/MissBeat by +$4.37 millionYoY Revenue GrowthN/AGyre Therapeutics Announcement DetailsQuarterQ4 2024Date3/17/2025TimeBefore Market OpensConference Call DateMonday, March 17, 2025Conference Call Time9:30AM ETUpcoming EarningsGyre Therapeutics' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Gyre Therapeutics Earnings HeadlinesHead-To-Head Comparison: Traws Pharma (NASDAQ:TRAW) vs. Gyre Therapeutics (NASDAQ:GYRE)September 29 at 6:14 AM | americanbankingnews.comHead to Head Contrast: Shineco (NASDAQ:SISI) and Gyre Therapeutics (NASDAQ:GYRE)September 24, 2026 | americanbankingnews.comThey're not telling you how bad this could getValuations are stretched to levels seen only a handful of times in the past century, while a growing debt spiral and lingering tariff shocks ripple through supply chains. Parkview Capital's new Market Crash Survival Guide breaks down what's really happening beneath the market's record highs and how retirement savers are responding. | Parkview Capital Group (Ad)Comparing Gyre Therapeutics (NASDAQ:GYRE) & Urogen Pharma (NASDAQ:URGN)September 21, 2026 | americanbankingnews.comGyre Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)August 12, 2026 | theglobeandmail.comSee More Gyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email. Email Address About Gyre TherapeuticsGyre Therapeutics (NASDAQ:GYRE) is a biotechnology company focused on developing therapies for fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and other conditions involving abnormal tissue scarring. The company’s research programs are centered on small-molecule treatments intended to address the underlying processes that contribute to fibrosis. Its lead investigational product is F351, also known as hydronidone, an orally administered anti-fibrotic compound designed to inhibit pathways involved in collagen production and tissue scarring. F351 has been studied in clinical programs for IPF and other fibrotic disorders, although its development status and regulatory availability may vary by geography. Gyre Therapeutics was formed through the transformation of Catalyst Biosciences following a 2023 transaction involving Gyre Pharmaceuticals and companies affiliated with GNI Group. Through its relationship with Gyre Pharmaceuticals, the company maintains a development and commercial presence in China while pursuing broader international opportunities, including clinical development in the United States.View Gyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
